Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?

Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?

Secondary bacterial infections manifest during or after a viral infection(s) and can lead to negative outcomes and sometimes fatal clinical complications. Research and development of clinical interventions is largely focused on the primary pathogen, with research on any secondary infection(s) being...

Full description

Bibliographic Details
Main Authors: Prasanth Manohar, Belinda Loh, Sudarsanan Athira, Ramesh Nachimuthu, Xiaoting Hua, Susan C. Welburn, Sebastian Leptihn
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Microbiology
Subjects:
secondary bacterial infection
pulmonary viruses
SARS-CoV-2
COVID-19
phage therapy
phage endolysins
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.01434/full
id doaj-6c48650c038843b2ad53decc9b999f50
record_format Article
spelling doaj-6c48650c038843b2ad53decc9b999f502020-11-25T03:24:19ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2020-06-011110.3389/fmicb.2020.01434561097Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?Prasanth Manohar0Prasanth Manohar1Belinda Loh2Sudarsanan Athira3Ramesh Nachimuthu4Xiaoting Hua5Xiaoting Hua6Susan C. Welburn7Susan C. Welburn8Sebastian Leptihn9Sebastian Leptihn10Sebastian Leptihn11Zhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, ChinaThe Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaZhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, ChinaAntibiotic Resistance and Phage Therapy Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, IndiaAntibiotic Resistance and Phage Therapy Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, IndiaDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaKey Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Hangzhou, ChinaZhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, ChinaInfection Medicine, Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United KingdomZhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, ChinaDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaInfection Medicine, Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United KingdomSecondary bacterial infections manifest during or after a viral infection(s) and can lead to negative outcomes and sometimes fatal clinical complications. Research and development of clinical interventions is largely focused on the primary pathogen, with research on any secondary infection(s) being neglected. Here we highlight the impact of secondary bacterial infections and in particular those caused by antibiotic-resistant strains, on disease outcomes. We describe possible non-antibiotic treatment options, when small molecule drugs have no effect on the bacterial pathogen and explore the potential of phage therapy and phage-derived therapeutic proteins and strategies in treating secondary bacterial infections, including their application in combination with chemical antibiotics.https://www.frontiersin.org/article/10.3389/fmicb.2020.01434/fullsecondary bacterial infectionpulmonary virusesSARS-CoV-2COVID-19phage therapyphage endolysins
collection DOAJ
language English
format Article
sources DOAJ
author Prasanth Manohar
Prasanth Manohar
Belinda Loh
Sudarsanan Athira
Ramesh Nachimuthu
Xiaoting Hua
Xiaoting Hua
Susan C. Welburn
Susan C. Welburn
Sebastian Leptihn
Sebastian Leptihn
Sebastian Leptihn
spellingShingle Prasanth Manohar
Prasanth Manohar
Belinda Loh
Sudarsanan Athira
Ramesh Nachimuthu
Xiaoting Hua
Xiaoting Hua
Susan C. Welburn
Susan C. Welburn
Sebastian Leptihn
Sebastian Leptihn
Sebastian Leptihn
Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
Frontiers in Microbiology
secondary bacterial infection
pulmonary viruses
SARS-CoV-2
COVID-19
phage therapy
phage endolysins
author_facet Prasanth Manohar
Prasanth Manohar
Belinda Loh
Sudarsanan Athira
Ramesh Nachimuthu
Xiaoting Hua
Xiaoting Hua
Susan C. Welburn
Susan C. Welburn
Sebastian Leptihn
Sebastian Leptihn
Sebastian Leptihn
author_sort Prasanth Manohar
title Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
title_short Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
title_full Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
title_fullStr Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
title_full_unstemmed Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?
title_sort secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics?
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2020-06-01
description Secondary bacterial infections manifest during or after a viral infection(s) and can lead to negative outcomes and sometimes fatal clinical complications. Research and development of clinical interventions is largely focused on the primary pathogen, with research on any secondary infection(s) being neglected. Here we highlight the impact of secondary bacterial infections and in particular those caused by antibiotic-resistant strains, on disease outcomes. We describe possible non-antibiotic treatment options, when small molecule drugs have no effect on the bacterial pathogen and explore the potential of phage therapy and phage-derived therapeutic proteins and strategies in treating secondary bacterial infections, including their application in combination with chemical antibiotics.
topic secondary bacterial infection
pulmonary viruses
SARS-CoV-2
COVID-19
phage therapy
phage endolysins
url https://www.frontiersin.org/article/10.3389/fmicb.2020.01434/full
work_keys_str_mv AT prasanthmanohar secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT prasanthmanohar secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT belindaloh secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT sudarsananathira secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT rameshnachimuthu secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT xiaotinghua secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT xiaotinghua secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT susancwelburn secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT susancwelburn secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT sebastianleptihn secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT sebastianleptihn secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
AT sebastianleptihn secondarybacterialinfectionsduringpulmonaryviraldiseasephagetherapeuticsasalternativestoantibiotics
_version_ 1724602257019764736

Similar Items